Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pneumonia I: Introduction01:30

Pneumonia I: Introduction

625
Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
625
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

689
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
689
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

2.3K
The pathophysiology of pneumonia involves the following steps:
2.3K
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

3.3K
Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
3.3K
Pneumonia IV: Management01:28

Pneumonia IV: Management

660
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
660
Healthcare Associated Infections I: Iatrogenic, Exogenic and Endogenic01:26

Healthcare Associated Infections I: Iatrogenic, Exogenic and Endogenic

5.2K
Healthcare-associated infections (HAIs) occur in a healthcare facility while a person receives care for another ailment. This category also includes work-related infections among healthcare staff.
HAIs significantly increase the cost of health care. Extended stays in healthcare institutions, increased disability, increased costs of medications, including specialized antibiotics, and prolonged recovery times add to the patient's expenses and the healthcare institution and funding bodies.
5.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Predictive accuracy of population meropenem models in critically ill pneumonia patients.

Antimicrobial agents and chemotherapy·2026
Same author

Longitudinal clinical proteomics reveals pneumonia type-specific protein biomarkers and autoantibodies.

JCI insight·2026
Same author

Pathogen-specific host responses define distinct pneumonia endotypes in the human lung.

bioRxiv : the preprint server for biology·2026
Same author

Targeted next-generation sequencing for microbial and clinical diagnosis: a prospective controlled comparison between sputum and bronchoalveolar lavage fluid in patients with community-acquired pneumonia.

BMC infectious diseases·2026
Same author

Bayesian Dosing Simulator (BDS): A Pharmacokinetic Modeling Tool for Optimized Antibiotic Therapy.

Pharmacotherapy·2026
Same author

Development of a Pilot Machine Learning Model to Predict Successful Short-Term Treatment Success in Critically Ill Patients With Community-Acquired Pneumonia.

CHEST critical care·2026

Related Experiment Video

Updated: Dec 18, 2025

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

15.4K

Staphylococcus aureus Pneumonia in the Community.

Hangyong He1, Richard G Wunderink2

  • 1Department of Respiratory and Critical Care Medicine, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.

Seminars in Respiratory and Critical Care Medicine
|June 11, 2020
PubMed
Summary

Staphylococcus aureus is a growing cause of community-acquired pneumonia (CAP), especially severe cases from MRSA, leading to critical illness. Early recognition and appropriate antibiotic therapy are crucial for managing S. aureus CAP.

More Related Videos

Visualization of Streptococcus pneumoniae within Cardiac Microlesions and Subsequent Cardiac Remodeling
08:25

Visualization of Streptococcus pneumoniae within Cardiac Microlesions and Subsequent Cardiac Remodeling

Published on: April 7, 2015

9.4K
A Mouse Model for the Transition of Streptococcus pneumoniae from Colonizer to Pathogen upon Viral Co-Infection Recapitulates Age-Exacerbated Illness
12:21

A Mouse Model for the Transition of Streptococcus pneumoniae from Colonizer to Pathogen upon Viral Co-Infection Recapitulates Age-Exacerbated Illness

Published on: September 28, 2022

2.9K

Related Experiment Videos

Last Updated: Dec 18, 2025

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

15.4K
Visualization of Streptococcus pneumoniae within Cardiac Microlesions and Subsequent Cardiac Remodeling
08:25

Visualization of Streptococcus pneumoniae within Cardiac Microlesions and Subsequent Cardiac Remodeling

Published on: April 7, 2015

9.4K
A Mouse Model for the Transition of Streptococcus pneumoniae from Colonizer to Pathogen upon Viral Co-Infection Recapitulates Age-Exacerbated Illness
12:21

A Mouse Model for the Transition of Streptococcus pneumoniae from Colonizer to Pathogen upon Viral Co-Infection Recapitulates Age-Exacerbated Illness

Published on: September 28, 2022

2.9K

Area of Science:

  • Infectious Diseases
  • Pulmonology
  • Microbiology

Background:

  • Staphylococcus aureus is an increasing cause of community-acquired pneumonia (CAP), particularly severe forms (SCAP).
  • Methicillin-resistant S. aureus (MRSA), especially community-associated strains (CA-MRSA), poses a significant threat, causing severe illness and death.
  • Panton-Valentine leukocidin (PVL) is a key virulence factor in severe S. aureus infections.

Purpose of the Study:

  • To highlight Staphylococcus aureus as an emergent cause of CAP.
  • To discuss the clinical features, diagnostic methods, and treatment strategies for S. aureus CAP.
  • To emphasize the challenges posed by CA-MRSA and PVL-positive strains.

Main Methods:

  • Review of clinical features suggestive of S. aureus CAP, including influenza coinfection, hemoptysis, multilobar infiltrates, and neutropenia.
  • Recommendations for diagnostic workup, including Gram stains, cultures, PCR, and blood cultures for severe cases.
  • Outline of treatment guidelines for methicillin-susceptible S. aureus (MSSA) and MRSA CAP.

Main Results:

  • S. aureus is a significant pathogen in CAP, with MRSA strains associated with higher mortality.
  • PVL-producing CA-MRSA strains are emerging in healthy individuals.
  • Specific clinical signs and diagnostic tests aid in early identification.

Conclusions:

  • Prompt diagnosis and appropriate antimicrobial selection are critical for improving outcomes in S. aureus CAP.
  • Cefazolin, oxacillin, or ceftaroline are recommended for MSSA CAP.
  • Linezolid is the preferred agent for CA-MRSA pneumonia; combination therapy may be considered for PVL-positive MRSA CAP.